We show here that dual targeting of JAK2 and ERK1/2 leads to an enhanced therapeutic performance in several MPN settings and thus should be pursued as a mechanism-based therapeutic approach for MPN patients. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.